Cancer Crusade at 40

Cancer Crusade at 40
As a service to the community AAAS and Science are making this special section FREE with registration - Register Now

From Science

Introduction to Special Issue

Celebrating an Anniversary

Science commemorates the 40th anniversary of the U.S. National Cancer Act, which provided a massive stimulus for cancer research.


Combining Targeted Drugs to Stop Resistant Tumors

Researchers hope to figure out how tumors escape; they aim to turn months of survival into years.


Can Treatment Costs Be Tamed?

More patients and the rising costs of new cancer treatments spark debate over how much is too much—and who should decide.


A Push to Fight Cancer in the Developing World

Cancer and other chronic diseases have received little attention from global health advocates. That's beginning to change.


Making Her Life an Open Book to Promote Expanded Care

Felicia Knaul, a health economist at Harvard Medical School in Boston, is one half of a Mexican-Canadian power couple that aims to end the neglect of cancer as a disease of the poor—and will succeed, if anyone can, say colleagues.


Brothers in Arms Against Cancer

Cancer researchers are trying to harness siblings of p53, the famous tumor-blocking protein.


Exploring the Genomes of Cancer Cells: Progress and Promise

An overview of cancer genomic efforts to date, and how they're being exploited to improve diagnosis and therapy of the disease.


A Perspective on Cancer Cell Metastasis

Metastasis causes most cancer deaths, yet this process remains one of the disease's most enigmatic aspects.


Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

Exploring a unifying conceptual framework that integrates the immune system's dual host-protective and tumor-promoting roles.


From Science Signaling

Editorial Guide

Focus Issue: Rendering Resistance Futile

Understanding the pathways that mediate drug resistance is key to developing new cancer therapies.

Research Article

c-MYC Suppresses BIN1 to Release Poly(ADP-ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance

c-MYC promotes cisplatin resistance by enabling the increased activity of a DNA repair enzyme.


MYC, PARP1, and Chemoresistance: BIN There, Done That?

Enhanced capacity for DNA repair may contribute to chemoresistance in cancers with dysregulated c-MYC.

Research Article

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

Resistance to cancer therapeutics targeting the second kinase in a three-kinase cascade involves amplification of the upstream kinase, not the inhibited kinase.


Resistance to MEK Inhibitors: Should We Co-Target Upstream?

Amplification of an upstream kinase in a three-kinase module confers resistance to cancer drugs that target a downstream kinase.

Research Article

Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl and Negative Feedback Mechanisms Controlling Src Signaling

Negative feedback fails to limit Src family kinase activity in the presence of Bcr-Abl, an oncoprotein that drives leukemia.



Negative feedback mechanisms fail to limit Src family kinase activity in leukemias driven by the oncoprotein Bcr-Abl.


From Science Translational Medicine


A National Cancer Clinical Trials System for Targeted Therapies

Clinical cancer research requires a well-supported and efficient national clinical trials network that engages in innovative trials of modern cancer therapies.


Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

In the testing of targeted cancer therapies, new issues can complicate the decision by patients or providers to participate in clinical trials.

Research Article

Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis

Breast cancer methylomes contribute to metastatic potential, modulate the metastasis transcriptome, and predict disease outcome.

Research Article

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.



A conversation with Timothy Chan about a new way to predict breast cancer metastasis.

Business Office Supplement

Translating Cancer Research In The New Millennium

As cancer research reaches deeper into the 'omics, new challenges and employment opportunities in the field await discovery.


Sequencing Cancer Genomes: Targeted Cancer Therapies

View in Video Portal


Science Podcast

Targeted cancer therapy, progress with cancer genomes, mechanisms of metastasis, immunity's role in cancer, and more.

Science Careers


Conducting Cancer Clinical Trials

Training courses teach young cancer researchers the skills needed to design and carry out clinical trials.


Q&A: Finding and Exploiting Cancer's Weaknesses

Clinician-investigator David Solit studies the genetic basis of cancer tumors and looks for novel therapies that target specific mutations.

Related Resources